BioPharma Dive September 30, 2024
The high-profile biotech, which has lost most of its market value in the last two years, will develop fewer internal programs and seek partners for others.
Prime Medicine will streamline research in a bid to focus on what its executives believe to be its most high-value programs, the company said Monday.
In a pair of announcements, Prime revealed plans to trim its pipeline as well as partner with Bristol Myers Squibb. Both are part of a broader initiative that, according to Prime, will help the company get the most out of its technology, a precision gene editing approach known as “prime editing.”
“We’re not going to push all of these programs into the clinic ourselves,” said Allan Reine, the company’s...
Today's Sponsors
Today's Sponsor